Book Description

Recent media reports and law enforcement actions have highlighted the problem of prescription drug fraud, waste, and abuse in the U.S. Medicare, and the Part D prescription drug benefit, are susceptible to such fraud -- a risk made greater by Medicare's size, scope, and complexity. Questions have been raised about the Department of Health and Human Services' (HHS) Centers for Medicare & Medicaid Services' (CMS's) oversight of its activities to address fraud, waste, and abuse in Part D, as well as oversight of the contractors tasked with this work. This report examined: (1) practices for promoting prescription drug program integrity; and (2) the extent that CMS's oversight of Medicare Part D program integrity, including the program integrity contractors, reflects these practices. Tables and figures. This is a print on demand report.